John C. McKinley

John C. McKinley

Auto-generated profile, based on publicly available information

John C. McKinley

Edinburgh Orthopaedics, Royal Infirmary of Edinburgh, 51 Little France Crescent, Edinburgh EH16 4SA, UK

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2020 in The Foot
Verified
Journal Article
Closed access
WMW. McMurrich
W. McMurrich
APA. Peters
A. Peters
MEM. Ellis
M. Ellis
HSH. Shalaby
H. Shalaby
GBG. Baer
G. Baer
JMJ.C. McKinley
J.C. McKinley

16 October 2023 in Journal of Bone and Joint Surgery
Verified
Journal Article
Open access
DTDavid Townshend
David Townshend
ABAndrew Bing
Andrew Bing
CBChris Blundell
Chris Blundell
TCTim Clough
Tim Clough
JDJames Davenport
James Davenport
AGAndrew Goldberg
Andrew Goldberg
The fixed-bearing Infinity implant (Wright Medical Group) for total ankle arthroplasty (TAA) was introduced to the U.K. market in 2014 and has rapidly become the most commonly used TAA implant. This is a follow-up report of a multicenter, non-designer, prospective observational study of 503 Infinity fixed-bearing TAA implants. The average follow-up of patients in the current report was 44.9 months (range, 28.3 to 63.9 months). The primary aim was to assess survivorship, complications, and reoperations. Secondary aims were to assess radiographic outcomes and patient-reported outcome measures (PROMs) and the influence of patient factors at 2 years. Four hundred and sixty-nine implants were evaluated at 2-year follow-up. Fifteen patients died, 8 withdrew, and 3 were lost to follow-up. The 2-year survivorship was 98.8%, and the non-revision reoperation rate was 2.8%. There was a significant improvement across all functional outcome scores from baseline to 2 years. The early experience and small rate of adverse events reported in this study continue to support the use of the Infinity TAA implant for the treatment of end-stage ankle arthritis. Level of Evidence: Therapeutic Level II. See Instructions for Authors for a complete description of levels of evidence.

1 July 2016 in The Bone & Joint Journal
Verified
Journal Article
Closed access
Nicholas David ClementNicholas David Clement
Nicholas David Clement
DMDeborah Jane Macdonald
Deborah Jane Macdonald
GDG. F. Dall
G. F. Dall
IAIshfaq Abdulrahiman Ahmed
Ishfaq Abdulrahiman Ahmed
ADA. D. Duckworth
A. D. Duckworth
JMJ. McKinley
J. McKinley
Aims: To examine the mid-term outcome and cost utility of the BioPro metallic hemiarthroplasty for the treatment of hallux rigidius. Patients and Methods: We reviewed 97 consecutive BioPro metallic hemiarthroplasties performed in 80 patients for end-stage hallux rigidus, with a minimum follow-up of five years. There were 19 men and 61 women; their mean age was 55 years (22 to 74). No patient was lost to follow-up. Results: A total of 12 patients (15 first metatarso-phalangeal joints (MTPJs)) required a revision; one for infection, two for osteolysis and 12 for pain. The all cause rate of survival at five years was 85.6% (95% confidence interval (CI) 83.5 to 87.9). Younger age was a significant predictor of revision (odds ratio 1.09, 95% CI 1.02 to 1.17, p = 0.014) on excluding infection and adjusting for confounding variables (Cox regression). Significant improvements were demonstrated at five years in the Manchester Oxford Foot Questionnaire (13.9, 95% CI 10.5 to 17.2) and in the physical component of the Short Form-12 score (6.5, 95% CI 4.1 to 8.9). The overall rate of satisfaction was 75%. The cost per quality adjusted life year at five years, accounting for a 14% rate of revision was between £4431 and £6361 depending on the complexity and morbidity of the patient. Conclusion: The BioPro hemiarthroplasty offers good short to mid-term functional outcome and is a cost effective intervention. The relatively high revision rate is associated with younger age and perhaps the use of this implant should be limited to older patients. Cite this article: Bone Joint J 2016;98-B:945–51.

1 July 2011 in Foot & Ankle International
Verified
Journal Article
Closed access
JMJohn C. McKinley
John C. McKinley
NSNicholas Shortt
Nicholas Shortt
CACalum Arthur
Calum Arthur
CGCharlotte Gunner
Charlotte Gunner
DMDeborah Jane Macdonald
Deborah Jane Macdonald
SBSteffen J. Breusch
Steffen J. Breusch
Background: We report a consecutive series of pantalar arthrodeses in patients with rheumatoid arthritis, using a single laterally based incision and autologous bone graft. Materials and Methods: All operations were performed by a single surgeon and were assessed preoperatively and at 6 and 12 months postoperatively. The levels of patient satisfaction, functional improvement, and pain scores of the foot following surgery were recorded along with radiological parameters. Seventeen patients (two male and 15 female) underwent 18 hindfoot surgeries and were assessed preoperatively using the SF-12 General Health survey questionnaire, Manchester-Oxford Foot Survey, and pain scores. Results: We found a significant improvement in pain levels and SF-12 scores. In addition, the patients reported a high level of satisfaction with the outcome of surgery and improvement in function. Conclusion: The results show that pantalar arthrodesis is a very effective operative treatment for severe ankle and concomitant hindfoot disease. The treatment period is prolonged and patients should be counseled appropriately. Level of Evidence: IV, Retrospective Case Series

1 September 2011 in Foot and Ankle Surgery
Verified
Journal Article
Closed access
RARaymond E. Anakwe
Raymond E. Anakwe
SMScott D. Middleton
Scott D. Middleton
CTColin E. Thomson
Colin E. Thomson
JMJohn C. McKinley
John C. McKinley

1 December 2021 in The Foot
Verified
Journal Article
Closed access
ZPZach J. Place
Zach J. Place
DMDeborah Jane Macdonald
Deborah Jane Macdonald
NCNicholas D. Clement
Nicholas D. Clement
HSHisham Shalaby
Hisham Shalaby
JMJohn C. McKinley
John C. McKinley